SHANDONG SANYUAN BIOTECHNOLOGY CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.65 CNY | -0.16% |
|
+11.76% | +9.59% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 7,891 | 5,843 | 6,404 | - |
| Enterprise Value (EV) 1 | 7,891 | 5,843 | 6,404 | 6,404 |
| P/E ratio | 47.6 x | 99.6 x | 51 x | 39.6 x |
| Yield | 1.79% | 0.87% | 0.98% | 1.26% |
| Capitalization / Revenue | 11.7 x | 11.7 x | 8.32 x | 7.27 x |
| EV / Revenue | 11.7 x | 11.7 x | 8.32 x | 7.27 x |
| EV / EBITDA | 35.1 x | 48.3 x | 33.2 x | 25.8 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | 1.71 x | 1.29 x | 1.39 x | - |
| Nbr of stocks (in thousands) | 202,326 | 202,326 | 202,326 | - |
| Reference price 2 | 39.00 | 28.88 | 31.65 | 31.65 |
| Announcement Date | 4/26/23 | 4/22/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 1,675 | 674.9 | 499.5 | 770 | 881 |
| EBITDA 1 | - | 650.2 | 224.8 | 121 | 193 | 248 |
| EBIT 1 | - | 619.8 | 186.1 | 61.38 | 131 | 180 |
| Operating Margin | - | 36.99% | 27.57% | 12.29% | 17.01% | 20.43% |
| Earnings before Tax (EBT) 1 | - | 619.9 | 184 | 61.71 | 131 | 180 |
| Net income 1 | 232.6 | 535.4 | 163.7 | 58.87 | 125 | 162 |
| Net margin | - | 31.96% | 24.25% | 11.79% | 16.23% | 18.39% |
| EPS 2 | 1.533 | 3.527 | 0.8200 | 0.2900 | 0.6200 | 0.8000 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.6667 | 0.7000 | 0.2500 | 0.3100 | 0.4000 |
| Announcement Date | 7/8/21 | 4/26/22 | 4/26/23 | 4/22/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 68.9% | 3.8% | 1.29% | 2.7% | 3.5% |
| ROA (Net income/ Total Assets) | - | 44.3% | 5.03% | - | 2.5% | 3.2% |
| Assets 1 | - | 1,208 | 3,252 | - | 5,000 | 5,062 |
| Book Value Per Share 2 | - | 6.890 | 22.80 | 22.40 | 22.80 | - |
| Cash Flow per Share 2 | - | 4.230 | 0.4200 | 0.2800 | 0.9700 | - |
| Capex 1 | - | 434 | 243 | 123 | 113 | 116 |
| Capex / Sales | - | 25.93% | 35.96% | 24.62% | 14.68% | 13.17% |
| Announcement Date | 7/8/21 | 4/26/22 | 4/26/23 | 4/22/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
31.65
CNY
Average target price
32
CNY
Spread / Average Target
+1.11%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9.59% | 886M | |
| -0.03% | 2B | |
| +0.51% | 1.85B | |
| +1.80% | 1.2B | |
| -10.92% | 1.09B | |
| -0.28% | 974M | |
| +1.36% | 931M | |
| -8.88% | 921M | |
| +3.50% | 825M | |
| +4.62% | 730M |
- Stock Market
- Equities
- 301206 Stock
- Financials Shandong Sanyuan Biotechnology Co.,Ltd.